Oncopeptides

About

Oncopeptides AB is a privately held clinical stage company developing melflufen, a peptidase potentiated therapy for multiple myeloma.

Stockholm,Stockholms Lan,Sweden
251 - 500
https://www.oncopeptides.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: €30M
Industries: Biotechnology,Clinical Trials,Pharmaceutical
Founded date: Jan 1, 2000
Number Of Employee: 251 - 500
Operating Status: Active
Stock Symbol: sto:ONCO

Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015.
Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Melflufen is a very potent anti-angiogenetic compound, triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA. Melflufen is currently undergoing Phase 2 efficacy studies in patients with relapsed and relapsed-refractory multiple myeloma. The peptidase targeting causes melflufen and its metabolites to accumulate in the diseased cells. This results in targeted delivery of the active moieties to the cancer cells, and thereby better treatment of the disease.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

6

€30M kr2.48B

Oncopeptides has raised a total of €30M kr2.48B in funding over 2 rounds. Their latest funding was raised on Nov 25, 2022 from a Post-IPO Debt round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Nov 25, 2022	Post-IPO Debt	€30M	1	European Investment Bank	—	Detail
Sep 7, 2022	Grant	kr5M	1	Vinnova	—	Detail
Mar 10, 2021	Post-IPO Equity	kr1.10B	2	—	—	Detail
Jun 28, 2019	Post-IPO Equity	kr727M	—	—	—	Detail
Mar 2, 2017	IPO	kr649M	—	—	—	Detail